Actively Recruiting
Transcranial Direct Current Stimulation in Children With Autism
Led by New York State Institute for Basic Research · Updated on 2026-02-23
24
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Although many children diagnosed with autism spectrum disorder (ASD) make significant progress in learning and their cognitive skills improve with applied behavior analysis (ABA), there are a significant number of children who show an absence or a plateau in various skills. Deficits in executive functioning are likely to be involved in many of these cognitive and learning disabilities due to poor functioning of the prefrontal cortex. Currently, the use of biological methods for improving learning and cognition is largely unexplored in research and practice. The aim of this study is to use of transcranial direct current stimulation (tDCS) in combination with ABA to improve the acquisition of educational programs for students with ASD. tDCS is a low-level electrical neurostimulation and is most effective when used in combination with an active training or teaching, facilitating the neuronal circuits used for that task. tDCS has been used for various indications over a couple of decades and has been shown to be very safe and has been well-tolerated by children with ASD. The mechanism of tDCS is not clear, however animal studies show that tDCS can stimulate the flow of calcium ions through channels in the astrocytes, activating them, and facilitating their role in synapse formation and therefore learning.
CONDITIONS
Official Title
Transcranial Direct Current Stimulation in Children With Autism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females between 5 and 12 years with autism
- Enrolled in an ABA program (school or in-home) supervised by a Board Certified Behavior Analyst (BCBA)
- Stable medical and behavioral treatments for at least 4 weeks prior to, and during the study
- Able to tolerate wearing tDCS as determined during a week-long daily desensitization training.
You will not qualify if you...
- Any implanted metal device (heart pacemaker, cochlear implant, surgical clips, etc.)
- Severe neurological disorders such as traumatic brain injury, brain tumor, intracranial infection
- Seizure disorder with a seizure within the last two years
- Skull defect
- Peripheral blindness or deafness
- Taking medications that may affect tDCS, including sodium or calcium channel blockers, NMDA receptor-affecting drugs, serotonin reuptake inhibitors, dopamine agents, norepinephrine agents, seizure-threshold lowering drugs, barbiturates, benzodiazepines, meprobamate, or chloral hydrate within the past 4 weeks
- Acute skin disease
- History of magnetic or electrical stimulation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
New York State Institute for Basic Research
Staten Island, New York, United States, 10314
Actively Recruiting
Research Team
J
J. Helen Yoo, Ph.D.
CONTACT
E
Eric London, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here